Hundreds of breakthrough treatments are transforming patients’ lives in the US — but still aren’t available in Europe.

In this short extract, Pierre-Henri Belin, the Co-Founder and CEO of Xcube.Bio, reveals the shocking scale of this innovation gap… and why it’s growing.

The full episode drops tomorrow on Pharma minds — don’t miss it!

What you will learn in the full episode of tomorrow :

◾️ The alarming gap between the United States and Europe — with more than 100 new drugs available in the US but still not accessible to European patients.

◾️ Why this gap exists, from fragmented regulatory systems to national-level decision-making and the lack of early collaboration between key actors.

◾️ The consequences for patients, innovation, and the competitiveness of Europe’s healthcare ecosystem.

◾️ Pierre-Henri’s proposed model, built on transparency, collaboration, and shared responsibility — connecting innovators, regulators, and patients earlier in the process.

◾️ A message of hope, showing that Europe can reinvent its system without sacrificing safety or trust, but only if we act collectively and decisively.

A clear, concrete, and inspiring episode that sheds light on how Europe can regain its leadership in healthcare innovation.

See you tomorrow!

---

🎧 New here? To get a quick overview of the episodes, download “25 Tips for Purposeful Leadership”, a guide inspired by the best advice shared by my guests.

🤝 Want to connect or talk about your current challenges? Let’s connect on LinkedIn.

📩 Curious to dive deeper into the major shifts in the pharma and healthcare ecosystem? Subscribe to the Pharma Minds newsletter.

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

[PREVIEW] Why European patients still can’t access 100 new drugs ?

Pharma Minds